The £30 million Big Beat Challenge was won by CureHeart, with the money set to be used to create an injectable treatment for those with genetic heart muscle problems.
One in 250 individuals across the globe may be impacted by genetic cardiomyopathies, which are responsible for thousands of deaths. Additionally, there is a 50% risk that those who have the illness pass it on to their own offspring.
“Cureheart is working to create cutting-edge gene therapy methods that could alter or entirely stop the defective genes that underlie heart muscle problems“
Cureheart is working to create cutting-edge gene therapy methods that could alter or entirely stop the defective genes that underlie the disorders. The £30 million prize will aid in the development of initial treatments for hereditary heart muscle ailments.
Professor Hugh Watkins, Lead investigator of CureHeart, commented that “after 30 years of research, we have discovered many of the genes and specific genetic faults responsible for different cardiomyopathies, and how they work. We believe that we will have a gene therapy ready to start testing in clinical trials in the next five years.”
Sir Nilesh Samani, Medical Director at the British Heart Foundation, added that “this is a defining moment for cardiovascular medicine. Once successful, the same gene editing innovations could be used to treat a whole range of common heart conditions where genetic faults play a major role.”